Masparen Retard (Galantamine)

Galantamine works by reversibly inhibiting acetylcholinesterase, the enzyme that breaks down acetylcholine, thereby increasing acetylcholine levels in the synapse. It also allosterically modulates nicotinic acetylcholine receptors, further supporting neuronal signaling involved in memory and cognition.

The specific dose of Masparen Retard is determined by the prescribing clinician based on the patient’s clinical condition, age, renal and hepatic function, and response to therapy. Physicians typically start with a low dose and titrate upward as needed.

Safety data for galantamine in pregnancy and lactation are limited. Because potential risks cannot be ruled out, the product should generally be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.

To place an order, submit an enquiry on the Masparen Retard product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

The most common alternative in the same class is donepezil, another acetylcholinesterase inhibitor. Both improve cognition in Alzheimer’s disease, but galantamine also modulates nicotinic receptors, which may offer additional benefits in some patients. Side‑effect profiles differ slightly, with galantamine more frequently causing gastrointestinal symptoms, while donepezil may be associated with muscle cramps.

Masparen Retard should be stored at ambient temperature below 25 °C, in the original packaging to protect it from moisture and light. Keep the tablets out of reach of children and avoid exposure to excessive heat or humidity.

Masparen Retard is administered orally as a tablet. It should be swallowed whole with a glass of water, preferably with food to reduce gastrointestinal discomfort, unless the prescriber advises otherwise.

Serious adverse events include severe liver injury, cardiac arrhythmias such as bradycardia, and seizures. Patients should be monitored for signs of hepatic dysfunction, unexplained heart rhythm changes, or new seizure activity, and seek immediate medical attention if these occur.

Masparen Retard is contraindicated in patients with known hypersensitivity to galantamine or any excipients, those with severe hepatic impairment, and individuals with a history of cardiac conduction abnormalities that could be worsened by bradycardia. Caution is also advised for patients with active peptic ulcer disease or uncontrolled asthma.